Basophil histamine release pathway

The basophil histamine release pathway is a complex biochemical signaling cascade that results in the exocytosis of histamine and other pro-inflammatory mediators from basophil granulocytes. This process is typically initiated by the cross-linking of allergen-specific IgE molecules bound to the high-affinity IgE receptor, FcεRI, on the cell surface (Source: PubMed - PMID: 24507349). Upon activation, a series of intracellular signaling events occur, involving the recruitment and activation of tyrosine kinases such as Spleen tyrosine kinase (Syk) and Bruton's tyrosine kinase (BTK), which ultimately lead to an increase in cytosolic calcium levels and granule fusion (Source: UniProt - P06730, Q06187). This pathway is a central component of type I hypersensitivity reactions and is heavily implicated in the pathogenesis of allergic diseases, including asthma, anaphylaxis, and chronic spontaneous urticaria (Source: NIH - StatPearls). Drugs targeting this pathway, such as the anti-IgE antibody omalizumab or various BTK inhibitors, aim to prevent the release of histamine to alleviate allergic symptoms and reduce systemic inflammation (Source: PubChem - CID 135311524). While the pathway itself is a biological process rather than a single molecular target, its individual components are major focal points for therapeutic development in immunology.

Other names

Basophil activation pathwayIgE-mediated basophil degranulationFcεRI-mediated signaling pathwayBasophil degranulation

Inhibition of IgE binding to the high-affinity IgE receptor (FcεRI) or pharmacological inhibition of downstream signaling components such as Bruton's tyrosine kinase (BTK) and Spleen tyrosine kinase (Syk) to prevent the release of inflammatory mediators.